About Curasight
Curasight is a company based in Copenhagen (Denmark) founded in 2013 by Carsten Haagen Nielsen and Jacob Madsen. It operates as a HealthTech. Curasight has raised $11.54 million across 4 funding rounds from investors including PreSeed Ventures. The company has 9 employees as of November 30, 2024. Curasight offers products and services including uTREAT® and uTRACE®. Curasight operates in a competitive market with competitors including OncoStem, PreludeDx, Miltel, POC Medical Systems and Inbiomotion, among others.
- Headquarter Copenhagen, Denmark
- Employees 9 as on 30 Nov, 2024
- Founders Carsten Haagen Nielsen, Jacob Madsen
- Stage Minicorn
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Curasight A/S
-
Annual Revenue
Not available
-
Net Profit
-$2.6 M (USD)-65as on Dec 31, 2022
-
EBITDA
-$2.37 M (USD)-55as on Dec 31, 2022
-
Total Equity Funding
$11.54 M (USD)
in 4 rounds
-
Latest Funding Round
$7.4 M (USD), Series A
Sep 22, 2020
- Investors
-
Employee Count
9
as on Nov 30, 2024
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Curasight
Curasight offers a comprehensive portfolio of products and services, including uTREAT® and uTRACE®.
Targeted radiation therapy is used for cancer treatment.
uPAR-PET imaging is used for cancer diagnosis accuracy.
People of Curasight
Unlock access to complete
Funding Insights of Curasight
Curasight has successfully raised a total of $11.54M across 4 strategic funding rounds. The most recent funding activity was a Series A round of $7.4 million completed in September 2020. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Curasight
Curasight has secured backing from 1 investor, including institutional investors. Prominent investors backing the company include PreSeed Ventures.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
-
|
Locked | Locked | Locked |
Investor details for Curasight
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Curasight
Investment portfolio details for Curasight
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Curasight
Detailed financials for Curasight
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Curasight Comparisons
Peer comparison for Curasight
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Curasight
Curasight operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as OncoStem, PreludeDx, Miltel, POC Medical Systems and Inbiomotion, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Prognostic tests for cancer detection and recurrence risk are developed.
|
|
| Locked | Locked | Locked |
Risk assessment tests for early-stage breast cancer are provided.
|
|
| Locked | Locked | Locked |
Telomere tests for aging detection and cellular senescence are provided.
|
|
| Locked | Locked | Locked |
Develops rapid tools for breast cancer detection and disease screening worldwide.
|
|
| Locked | Locked | Locked |
Biomarkers for predicting bone metastasis in cancer patients are developed.
|
Detailed competitors of Curasight
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Curasight
Complete news archive for Curasight
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Curasight
Curasight was founded in 2013 and raised its 1st funding round 1 year after it was founded.
Curasight is headquartered in Copenhagen, Denmark.
Ulrich Alexander Krasilnikoff is the current CEO of Curasight.
Curasight is a funded company, having raised a total of $11.54M across 4 funding rounds to date.
As of Nov 30, 2024, the latest employee count at Curasight is 9.
Curasight, a Danish biotech company, is dedicated to improving cancer care through innovative technologies. The company specializes in uPAR Theranostics, combining targeted uTREAT radiation therapy with precise uTRACE diagnostics to minimize harm to healthy tissue. Focus areas include brain and prostate cancer, with several phase II clinical trials completed or ongoing. Solutions are built on deep research into the uPAR system, aiming to enhance diagnosis and treatment outcomes in the healthcare sector.
Curasight's top competitors include PreludeDx, OncoStem and Gamma Medica.
Curasight offers uTREAT® and uTRACE®.
Curasight has 1 investor. Key investors include PreSeed Ventures.
The valuation of Curasight is $38.8M as of Sep 2020.